Neurotech

Just Published: Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases by Kauper et al.
Go to publication website.

Vincent Ling, Ph.D., to speak on Encapsulated Cell Technology, at Wyss Institute, Harvard Medical School, Boston, MA

Neurotech Pharmaceuticals relocates to 900 Highland Corporate Drive, Cumberland, Rhode Island

Vincent Ling, Ph.D., to speak on Delivery of Biologics via Encapsulated Cell Technology: NT-503 VEGF Antagonist for wet AMD, at Second Biennial Symposium on AMD, Schepens Eye Research Institute, Boston, MA

Go to Schepens

The FDA Orphan Product Division has awarded a grant ($1,459,330 – NIH R01 FD004100-01A1) to fund the study of NT-501 for RP using cone preservation as the endpoint (Jacque Duncan- University of California).

Konrad Kauper to speak “Developing Sight-Saving Therapeutics for Chronic Retinal Diseases” at LCA Conference, Philadelphia, PA,

Go to LCA foundation

NT-501 granted orphan-drug designation for macular telangiectasia type 2 (MacTel).

Go to FDA orphan-drug site

Vincent Ling, Ph.D., to speak on Delivery of Alternative Scaffolds Using Encapsulated Cell Technology at IBC Next Generation Protein Summit 2012, San Francisco, CA

Vincent Ling, Ph.D., to speak on Encapsulated Cell Technology: Next Frontier in Biotechnology at Rochester Institute of Technology, Rochester, NY

Vincent Ling, Ph.D., to speak on Encapsulated Cell Technology: A New Therapy for Biologics Delivery at IBC Antibody Therapeutics Meeting, San Diego, CA

Ted Danse, CEO, to present NT-503 VEGF-Antagonist Clinical Data Update at Ophthalmology Innovation Summit; Orlando, Florida

Ted Danse, CEO, to present Neurotech Encapsulated Cell Technology at BioChina, Shanghai

Konrad Kauper to speak “A Novel Approach to Treat Photoreceptor Degeneration: 18-Month Results for NT-501 Dry AMD/GA Study” at 3rd Ocular Diseases and Drug Discovery, Boston, MA

Go to LCA foundation

Neurotech's NT-501 Implant Demonstrates Statistically Significant Photoreceptor Preservation in Patients with Retinal Degenerative Disease

Go to article

Neurotech's NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy associated with Dry AMD as Reported in PNAS

Go to article

Results from Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

Go to article

Positive Results from Neurotech's NT-501 Phase 2 Dry AMD (Geographic Atrophy) Study Demonstrate Proof of Concept

Go to article

Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island

Go to article

Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications—Retinitis Pigmentosa and Dry Age-Related Macular Degeneration

Go to article

Neurotech Pharmaceuticals Announces Rhode Island Expansion Plan

Go to article

Neurotech Announces Completion of Enrollment of its Phase 2/3 Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies

Go to article

Neurotech Names Richard Small Chief Financial Officer

Go to article

Neurotech Initiates two Phase 2/3 Clinical Trials of NT-501 for the Treatment of Retinitis Pigmentosa

Go to article

Neurotech Completes $35 Million Private Equity Financing

Go to article

Neurotech Announces Publication of NT-501 Phase I Results in Proceedings of the National Academy of Sciences

Go to article

Neurotech Initiates a Phase 2 Clinical Trial of NT-501 for the Treatment of Dry Age Related Macular Degeneration

Go to article

Neurotech Names Ted Danse as New President and CEO

Go to article

Neurotech Announces Successful Completion of Phase 1

Go to article

Neurotech Board Changes

Go to article

Neurotech Completes Euro 12 Million Private Financing

Go to article

Neurotech Announces Initiation of a Phase 1 Clinical Trial to Evaluate the Safety of Ciliary Neurotrophic Factor Implant in the Eye

Go to article

Neurotech Strengthens Its Position In Ophthalmology Through Collaboration With Inserm and the Quinze-Vingts Hospital, Paris

Go to article

Neurotech Reports in IOVS that Encapsulated Cell Based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa

Go to article

Neurotech Refocuses on Ophthalmic Technologies

Go to article

Neurotech Announces Senior Management Changes

Go to article

Neurotech Signs License Agreement with Amgen

Go to article